New findings from a study of 20,000+ people presented November 10 at the 2018 American Heart Association meeting showed that non-valvular atrial fibrillation (AFib) patients taking Xarelto (rivaroxaban) experienced significantly fewer strokes compared to those taking warfarin, according to Janssen Pharmaceutical Companies of Johnson & Johnson.
Specifically, Xarelto reduced overall stroke by 27 percent, stroke severity by 62 percent, and 30-day post-stroke mortality by 64 percent.
“These data are a great complement to clinical evidence to ensure medicines perform as expected,” Dr. JoAnne Foody, executive director, medical affairs-cardiovascular at Janssen Inc., said. “With Xarelto showing clear and meaningful benefits over warfarin, we believe physicians will consider these findings when deciding how to manage patients with non-valvular AFib.”
Up to six million Americans have AFib, which puts them at an increased risk of stroke1, and one of three people with AFib will have a stroke at some point during their life2. Treatment guidelines currently recommend oral anticoagulants for stroke prevention in people with non-valvular AFib.
Xarelto remains the most studied oral Factor Xa inhibitor in the world today with more than 200,000 people evaluated in published real-world research since its approval, according to Janssen. Post-marketing studies and registries continue to confirm the safety and efficacy of Xarelto in routine clinical use across a broad spectrum of patients.
(Source: Janssen Pharmaceutical Companies of Johnson & Johnson)
